Fig. 8: Immunization of mice and evaluation of the immunogenicity of the dPNAG-CRM197 conjugates as vaccine candidates. | Nature Communications

Fig. 8: Immunization of mice and evaluation of the immunogenicity of the dPNAG-CRM197 conjugates as vaccine candidates.

From: Poly-β-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities

Fig. 8: Immunization of mice and evaluation of the immunogenicity of the dPNAG-CRM197 conjugates as vaccine candidates.The alternative text for this image may have been generated using AI.

A Schematic diagram of the immunogenicity evaluation. B, C Glycan microarray with non-acetylated dPNAG glycans. D, E Glycan microarray with acetylated dPNAG glycans. Mice (n = 5) were immunized i.m. with the same amounts (2 mg) of the different dPNAG-CRM197 conjugates and glycolipid C34. Mouse sera were collected 14 days after the third immunization. The binding profiles of the antibodies with (B, D) 1000-fold or (C and E) 8000-fold dilution were analyzed by glycan microarrays of the synthesized dPNAG glycans. The experiment was performed in biological replicates, and error bars represent the standard deviation from the mean of the data point (n = 10). Statistical analysis was performed with one-way ANOVA followed by Tukey’s multiple comparison test using GraphPad Prism version 10.4.0 for macOS. Multiple comparisons and P values are shown in Table S3. ****: p < 0.0001.

Back to article page